Fate Therapeutics (FATE) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ACCV
2. GMAB
3. IVBIY
4. IIB:IN
5. AZN
6. DRRD:IN
7. SMMT
8. RDY
9. CART
10. CLYM

Go back to Fate Therapeutics (FATE) Misses Q1 EPS by 1c

Fate Therapeutics Reports First Quarter 2014 Financial Results

May 13, 2014 4:01 PM EDT

Phase 2 PUMA Study of PROHEMA® in Adult Hematologic Malignancies Enrolling Patients

Phase 1b PROMPT Study of PROHEMA in Pediatric Hematologic Malignancies Cleared by FDA

IND Submission for Study of PROHEMA in Rare Genetic Disorders Expected in 2Q14

SAN DIEGO, May 13, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq: FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today reported clinical development updates and... More